For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative expenses | 13,697,817 | |||
| Research and development | 16,258,598 | |||
| Total operating expenses | 29,956,415 | |||
| Loss from operations | -29,956,415 | |||
| Interest income | 555,526 | |||
| Total other income | 555,526 | |||
| Loss before provision for income taxes | -29,400,889 | |||
| Provision for income taxes | 37,724 | |||
| Net loss | -29,438,613 | |||
| Net loss attributable to immix biopharma, inc. common stockholders | -29,438,613 | |||
| Foreign currency translation | 61,216 | |||
| Total other comprehensive income (loss) | 61,216 | |||
| Comprehensive loss | -29,377,397 | |||
| Basic EPS | -0.89 | |||
| Diluted EPS | -0.89 | |||
| Basic Average Shares | 32,965,706 | |||
| Diluted Average Shares | 32,965,706 | |||
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)